Further RCTs enrolling subjects with CKD are necessary to determine whether the favorable effects of SGLT2 inhibitors on renal outcomes beyond the increased risk of ketoacidosis among individuals with T1D. This evidence concerns the gene SLC5A2 and chronic kidney disease.